GRI Bio Raises a Total of 13.9 Million in Gross Proceeds Since the Beginning of 2024
| GRI Etf | USD 0.93 0.06 6.90% |
Under 57% of all GRI Bio's traders are looking to take a long position. The analysis of the overall investor sentiment regarding GRI Bio suggests that some traders are interested. GRI Bio's investing sentiment shows overall attitude of investors towards GRI Bio.
GRI |
Proceeds from recent exercise of warrants estimated to extend cash runway into mid Q1 2025, including interim data readout from Phase 2a biomarker study of lead program, GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis Current treatment options for IPF are limited with only 2 approved drugs which have significant side-effects, limited compliance and no impact on survival LA JOLLA, CA, Oct. 24, 2024 -- GRI Bio, Inc. , a b
Read at finance.yahoo.com
 |
GRI Bio Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards GRI Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
GRI Bio Fundamental Analysis
We analyze GRI Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GRI Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GRI Bio based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
GRI Bio is currently under evaluation in number of shares shorted as compared to similar ETFs. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
GRI Bio Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with GRI Bio etf to make a market-neutral strategy. Peer analysis of GRI Bio could also be used in its relative valuation, which is a method of valuing GRI Bio by comparing valuation metrics with similar companies.
Peers
GRI Bio Related Equities
| CCCC | C4 Therapeutics | 9.28 | ||||
| CNTB | Connect Biopharma | 7.89 | ||||
| DSGN | Design Therapeutics | 4.23 | ||||
| CUE | Cue Biopharma | 3.64 | ||||
| STTK | Shattuck Labs | 2.31 | ||||
| IKNA | Ikena Oncology | 1.80 | ||||
| EWTX | Edgewise Therapeutics | 1.15 | ||||
| CELC | Celcuity LLC | 0.94 | ||||
| GBIO | Generation Bio | 0.79 | ||||
| ANEB | Anebulo Pharmaceuticals | 0.64 | ||||
| HOWL | Werewolf Therapeutics | 0.54 | ||||
| AVTE | Aerovate Therapeutics | 1.54 | ||||
| ELYM | Eliem Therapeutics | 1.90 | ||||
| HCWB | HCW Biologics | 2.50 | ||||
| XLO | Xilio Development | 2.80 | ||||
| PASG | Passage Bio | 3.80 | ||||
| PRLD | Prelude Therapeutics | 5.83 | ||||
| GLUE | Monte Rosa | 9.85 |
Other Information on Investing in GRI Etf
GRI Bio financial ratios help investors to determine whether GRI Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GRI with respect to the benefits of owning GRI Bio security.